With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical ...

In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...

Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...

Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...

The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...

Rockville, Maryland Wednesday, January 15, 2025, 12:00 Hrs [IST] ...

III study in treating thyroid eye disease. The privately held company posted top-line efficacy and safety results from a phase IIb/III study of its lead candidate, linsitinib, which hits its primary ...

Shares of Regenxbio Inc . (NASDAQ: RGNX) surged 18.4% in pre-open trading Tuesday following the announcement of a strategic partnership with Nippon Shinyaku Co., Ltd. for the development and ...

REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO's gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS ...